Trial Profile
A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Garetosmab (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LUMINA-1
- Sponsors Regeneron Pharmaceuticals
- 01 Oct 2023 Primary endpoint(Time-weighted average (standardized area under the curve [AUC]) of the percent change from baseline in total lesion activity by 18F-NaF positron emission tomography (PET) using Baseline-Active HO Classic Mutation (AHOC)) has not been met according to Results published in the Nature Medicine.
- 01 Oct 2023 Results published in the Nature Medicine
- 11 Sep 2023 Results published in the Journal of Clinical Pharmacology